Mild Cognitive Impairment Clinical Trials

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.

U US GSK Clinical Trials Call Center

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.

F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

Background People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Objective To test whether a drug (anifrolumab) can improve blood …

Q Qiubai Li, Professor

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of CD19 Universal CAR-γδT cells in active severe systemic lupus erythematosus.

L Liyun Zhang, MD

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).

S Sanita Kandasami

Trial of Belimumab in Early Lupus

This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab …

j jiali tian, MD

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

A Study to Investigate the Tolerability, Safety,Pharmacokinetics and efficacy of GR1603 in subjects with Systemic Lupus Erythematosus ； GR1603 injection is a monoclonal antibody targeting IFNAR1, which can block IFNAR binding to type I interferons such as IFNα and be used to treat systemic lupus erythematosus.

G Gilles Blaison, Investigator

None

X Xiaomei Leng

Efficacy and Safety of Telitacicept in Early SLE

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with early stage of SLE .

Y YKO Teng, MD, PhD

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.